Clinical TrialApr 28, 2026, 08:32 AM
PYPD D-PLEX100 SHIELD II Trial Shows 64% Reduction in Severe Infections
AI Summary
PolyPid Ltd. announced it will present detailed analysis of the ASEPSIS score data from its Phase 3 SHIELD II trial of D-PLEX100 at the 45th Annual Meeting of the Surgical Infection Society on May 6, 2026. The analysis demonstrated a statistically significant 64% relative risk reduction in the proportion of patients with clinically significant wound infections (ASEPSIS score > 20). This outcome, alongside the previously reported 60% relative risk reduction in overall SSI incidence, indicates D-PLEX100 not only reduces infections but also lessens their severity, leading to better patient outcomes and significant hospital economic benefits.
Key Highlights
- PolyPid to present D-PLEX100 Phase 3 SHIELD II ASEPSIS score data at Surgical Infection Society meeting on May 6, 2026.
- Analysis showed 64% relative risk reduction (p=0.0103) in patients with ASEPSIS score greater than 20.
- D-PLEX100 reduced surgical site infection (SSI) events by 60% (p=0.0013) in the SHIELD II trial.
- Fewer and less severe SSIs translate to better patient outcomes and potential hospital economic benefits.
- D-PLEX100 provides a 30-day prolonged and continuous release of doxycycline at the surgical site.
- D-PLEX100 received Breakthrough Therapy designation from the USFDA for SSI prevention in elective colorectal surgery.